Anne M. Manicone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne M. Manicone has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Matthew E. Long
Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, College of Medicine, The Ohio State University Wexner Medical Center , Columbus, OH
7 shared publications Ke-Qin Gong
Division of Pulmonary, Critical Care and Sleep Medicine, and
5 shared publications- Sina A. Gharib
University of Washington
5 shared publications William C. Parks
Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, Calif
5 shared publications- Jourdan E. Brune
University of Washington
4 shared publications - Ke-Qin Gong
University of Washington
4 shared publications
Latest Publications
- 28 October 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
MEK2 Suppresses IL-4 Polarization via PPARγ and Negatively Impacts Macrophage Epithelial Crosstalk to Delay Repair
MEK2 is a highly conserved mitogen-activated protein kinase whose pathway activation is increased in both acute respiratory distress syndrome (ARDS) and murine acute lung injury (ALI). We previously demonstrated that leukocyte-specific Mek2 -/- mice have accelerated recovery from ALI, including earlier restoration of alveolar barrier function, indicating that leukocyte MEK2 prolongs lung injury. Here, we tested the hypothesis that MEK2 suppresses reparative IL-4-driven macrophage function. Transcriptional profiling of WT and Mek2 -/- bone marrow-derived macrophages (BMDM) revealed that MEK2 inhibits a subset of IL-4-dependent gene expression, including those enriched in wound repair pathways. Mechanistically, MEK2 is required for IL-4-induced ERK1/2 phosphorylation and the suppression of PPARγ levels. Pharmacologic inhibition of PPARγ abolished the enhanced IL-4-dependent gene expression observed in Mek2 -/- BMDMs, identifying PPARγ as a key mediator by which MEK2 restrains reparative macrophage polarization. To determine the functional relevance of these findings, we evaluated macrophage-supported alveolar epithelial type II (AT2) cell growth using an alveolar organoid model. IL-4-polarized macrophages enhanced AT2 proliferation in a PPARγ-dependent manner, whereas MEK2 suppressed this reparative effect. Together, these findings identify MEK2 as a negative regulator of reparative macrophage programming via suppression of PPARγ. Targeting MEK2 may represent a novel therapeutic strategy to accelerate repair of lung injury via enhancement of PPARγ activity in reparative macrophages.
- 28 October 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
MEK2 Suppresses IL-4 Polarization via PPARγ and Negatively Impacts Macrophage Epithelial Crosstalk to Delay Repair
MEK2 is a highly conserved mitogen-activated protein kinase whose pathway activation is increased in both acute respiratory distress syndrome (ARDS) and murine acute lung injury (ALI). We previously demonstrated that leukocyte-specific Mek2 -/- mice have accelerated recovery from ALI, including earlier restoration of alveolar barrier function, indicating that leukocyte MEK2 prolongs lung injury. Here, we tested the hypothesis that MEK2 suppresses reparative IL-4-driven macrophage function. Transcriptional profiling of WT and Mek2 -/- bone marrow-derived macrophages (BMDM) revealed that MEK2 inhibits a subset of IL-4-dependent gene expression, including those enriched in wound repair pathways. Mechanistically, MEK2 is required for IL-4-induced ERK1/2 phosphorylation and the suppression of PPARγ levels. Pharmacologic inhibition of PPARγ abolished the enhanced IL-4-dependent gene expression observed in Mek2 -/- BMDMs, identifying PPARγ as a key mediator by which MEK2 restrains reparative macrophage polarization. To determine the functional relevance of these findings, we evaluated macrophage-supported alveolar epithelial type II (AT2) cell growth using an alveolar organoid model. IL-4-polarized macrophages enhanced AT2 proliferation in a PPARγ-dependent manner, whereas MEK2 suppressed this reparative effect. Together, these findings identify MEK2 as a negative regulator of reparative macrophage programming via suppression of PPARγ. Targeting MEK2 may represent a novel therapeutic strategy to accelerate repair of lung injury via enhancement of PPARγ activity in reparative macrophages.
- Open Access
- 1 November 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (5) , 648-650
Reversing Alcohol-Dependent Effects on HIV Replication: Are There Roles for Pioglitazone and N-acetylcysteine?
- 1 November 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (5) , 648-650
Open AccessReversing Alcohol-Dependent Effects on HIV Replication: Are There Roles for Pioglitazone and N-acetylcysteine?
- Open Access
- 1 November 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 327 (5) , C1274-C1288
Regulation of versican expression in macrophages is mediated by canonical type I interferon signaling via ISGF3
We report the novel finding that versican expression is regulated by the interferon-stimulated gene factor 3 (ISGF3) arm of canonical type I Ifn signaling in LPS-stimulated macrophages. This pathway is distinct from mechanisms that control versican expression in other cell types. This suggests that macrophage-derived versican may play a role in limiting a potentially excessive inflammatory response. The detailed understanding of how versican expression is regulated in different cells could lead to unique approaches for enhancing its anti-inflammatory properties.
- 1 November 2024
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 327 (5) , C1274-C1288
Open AccessRegulation of versican expression in macrophages is mediated by canonical type I interferon signaling via ISGF3
We report the novel finding that versican expression is regulated by the interferon-stimulated gene factor 3 (ISGF3) arm of canonical type I Ifn signaling in LPS-stimulated macrophages. This pathway is distinct from mechanisms that control versican expression in other cell types. This suggests that macrophage-derived versican may play a role in limiting a potentially excessive inflammatory response. The detailed understanding of how versican expression is regulated in different cells could lead to unique approaches for enhancing its anti-inflammatory properties.
- 1 November 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 327 (5) , L740-L748
MAP2K1 dampens cigarette smoke-induced inflammation via suppression of type I interferon pathway activation
Activation of the mitogen-activated protein kinases (MAPK)-ERK1/2 pathway is present in COPD lung tissue compared with healthy lungs. Our study using mice deficient in myeloid Map2k1 reveals that Map2k1 is a critical determinant in modulating the severity of CS-induced lung inflammation via suppression of type I interferon responses, and its expression is protective.
- 1 November 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 327 (5) , L740-L748
MAP2K1 dampens cigarette smoke-induced inflammation via suppression of type I interferon pathway activation
Activation of the mitogen-activated protein kinases (MAPK)-ERK1/2 pathway is present in COPD lung tissue compared with healthy lungs. Our study using mice deficient in myeloid Map2k1 reveals that Map2k1 is a critical determinant in modulating the severity of CS-induced lung inflammation via suppression of type I interferon responses, and its expression is protective.
- Open Access
Regulation of Versican Expression in Macrophages is Mediated by Canonical Type I Interferon Signaling via ISGF3
Growing evidence supports a role for versican as an important component of the inflammatory response, with both pro- and anti-inflammatory roles depending on the specific context of the system or disease under investigation. Our goal is to understand the regulation of macrophage-derived versican and the role it plays in innate immunity. In previous work, we showed that LPS triggers a signaling cascade involving TLR4, the Trif adaptor, type I interferons, and the type I interferon receptor, leading to increased versican expression by macrophages. In the present study, we used a combination of chromatin immunoprecipitation, siRNA, chemical inhibitors, and mouse model approaches to investigate the regulatory events downstream of the type I interferon receptor to better define the mechanism controlling versican expression. Results indicate that transcriptional regulation by canonical type I interferon signaling via the heterotrimeric transcription factor, ISGF3, controls versican expression in macrophages exposed to LPS. This pathway is not dependent on MAPK signaling, which has been shown to regulate versican expression in other cell types. The stability of versican mRNA may also contribute to prolonged versican expression in macrophages. These findings strongly support a role for macrophage-derived versican as a type I interferon-stimulated gene and further our understanding of versican’s role in regulating inflammation.
Open AccessRegulation of Versican Expression in Macrophages is Mediated by Canonical Type I Interferon Signaling via ISGF3
Growing evidence supports a role for versican as an important component of the inflammatory response, with both pro- and anti-inflammatory roles depending on the specific context of the system or disease under investigation. Our goal is to understand the regulation of macrophage-derived versican and the role it plays in innate immunity. In previous work, we showed that LPS triggers a signaling cascade involving TLR4, the Trif adaptor, type I interferons, and the type I interferon receptor, leading to increased versican expression by macrophages. In the present study, we used a combination of chromatin immunoprecipitation, siRNA, chemical inhibitors, and mouse model approaches to investigate the regulatory events downstream of the type I interferon receptor to better define the mechanism controlling versican expression. Results indicate that transcriptional regulation by canonical type I interferon signaling via the heterotrimeric transcription factor, ISGF3, controls versican expression in macrophages exposed to LPS. This pathway is not dependent on MAPK signaling, which has been shown to regulate versican expression in other cell types. The stability of versican mRNA may also contribute to prolonged versican expression in macrophages. These findings strongly support a role for macrophage-derived versican as a type I interferon-stimulated gene and further our understanding of versican’s role in regulating inflammation.
- 1 May 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 66 (5) , 555-563
MAP2K2 Delays Recovery in Murine Models of Acute Lung Injury and Associates with Acute Respiratory Distress Syndrome Outcome
Acute respiratory distress syndrome (ARDS) remains a significant problem in need of new pharmaceutical approaches to improve its resolution. Studies comparing gene expression signatures in rodents and humans with lung injury reveal conserved pathways, including MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-related protein kinase) activation. In preclinical acute lung injury (ALI) models, inhibition of MAP2K1 (MAPK kinase 1)/MAP2K2 (MAPK kinase 2) improves measures of ALI. Myeloid cell deletion of MAP2K1 results in sustained MAP2K2 activation and nonresolving ALI, suggesting that MAP2K2 deactivation may be a key driver of ALI resolution. We used human genomic data from the iSPAAR (Identification of SNPs Predisposing to Altered Acute Lung Injury Risk) Consortium to assess genetic variants in MAP2K1 and MAP2K2 for association with mortality from ARDS. To determine the role of MAP2K2 in ALI recovery, we studied mice deficient in Map2k2 (Mek2 −/−) and wild-type control mice in ALI models. We identified a MAP2K2 variant that was associated with death in ARDS and MAP2K2 expression. In Pseudomonas aeruginosa ALI, Mek2 −/− mice had similar early alveolar neutrophilic recruitment but faster resolution of alveolar neutrophilia and vascular leak. Gene expression analysis revealed a role for MAP2K2 in promoting and sustaining select proinflammatory pathway activation in ALI. Bone marrow chimera studies indicate that leukocyte MAP2K2 is the key regulator of ALI duration. These studies implicate a role for MAP2K2 in ALI duration via transcriptional regulation of inflammatory programming with potential relevance to ARDS. Targeting leukocyte MAP2K2 may be an effective strategy to promote ALI resolution.
- 1 May 2022
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 66 (5) , 555-563
MAP2K2 Delays Recovery in Murine Models of Acute Lung Injury and Associates with Acute Respiratory Distress Syndrome Outcome
Acute respiratory distress syndrome (ARDS) remains a significant problem in need of new pharmaceutical approaches to improve its resolution. Studies comparing gene expression signatures in rodents and humans with lung injury reveal conserved pathways, including MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-related protein kinase) activation. In preclinical acute lung injury (ALI) models, inhibition of MAP2K1 (MAPK kinase 1)/MAP2K2 (MAPK kinase 2) improves measures of ALI. Myeloid cell deletion of MAP2K1 results in sustained MAP2K2 activation and nonresolving ALI, suggesting that MAP2K2 deactivation may be a key driver of ALI resolution. We used human genomic data from the iSPAAR (Identification of SNPs Predisposing to Altered Acute Lung Injury Risk) Consortium to assess genetic variants in MAP2K1 and MAP2K2 for association with mortality from ARDS. To determine the role of MAP2K2 in ALI recovery, we studied mice deficient in Map2k2 (Mek2 −/−) and wild-type control mice in ALI models. We identified a MAP2K2 variant that was associated with death in ARDS and MAP2K2 expression. In Pseudomonas aeruginosa ALI, Mek2 −/− mice had similar early alveolar neutrophilic recruitment but faster resolution of alveolar neutrophilia and vascular leak. Gene expression analysis revealed a role for MAP2K2 in promoting and sustaining select proinflammatory pathway activation in ALI. Bone marrow chimera studies indicate that leukocyte MAP2K2 is the key regulator of ALI duration. These studies implicate a role for MAP2K2 in ALI duration via transcriptional regulation of inflammatory programming with potential relevance to ARDS. Targeting leukocyte MAP2K2 may be an effective strategy to promote ALI resolution.
- Open Access
- 1 July 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 63 (1) , 9-10
Loss of C/EBPα in Chronic Cigarette Smoke Exposure: A SAD Day for Chronic Obstructive Pulmonary Disease
- 1 July 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 63 (1) , 9-10
Open AccessLoss of C/EBPα in Chronic Cigarette Smoke Exposure: A SAD Day for Chronic Obstructive Pulmonary Disease
- Open Access
- 8 April 2020
- Published by Springer Nature in Critical Care
- Vol. 24 (1) , 1-3
Alveolar MMP28 is associated with clinical outcomes and measures of lung injury in acute respiratory distress syndrome
- 8 April 2020
- Published by Springer Nature in Critical Care
- Vol. 24 (1) , 1-3
Open AccessAlveolar MMP28 is associated with clinical outcomes and measures of lung injury in acute respiratory distress syndrome
- 5 December 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (23)
MEK1 regulates pulmonary macrophage inflammatory responses and resolution of acute lung injury
The MEK1/2–ERK1/2 pathway has been implicated in regulating the inflammatory response to lung injury and infection, and pharmacologic MEK1/2 inhibitor compounds are reported to reduce detrimental inflammation in multiple animal models of disease, in part through modulation of leukocyte responses. However, the specific contribution of myeloid MEK1 in regulating acute lung injury (ALI) and its resolution remain unknown. Here, the role of myeloid Mek1 was investigated in a murine model of LPS-induced ALI (LPS-ALI) by genetic deletion using the Cre-floxed system ( LysM Cre × Mek fl ), and human alveolar macrophages from healthy volunteers and patients with acute respiratory distress syndrome (ARDS) were obtained to assess activation of the MEK1/2–ERK1/2 pathway. Myeloid Mek1 deletion results in a failure to resolve LPS-ALI, and alveolar macrophages lacking MEK1 had increased activation of MEK2 and the downstream target ERK1/2 on day 4 of LPS-ALI. The clinical significance of these findings is supported by increased activation of the MEK1/2–ERK1/2 pathway in alveolar macrophages from patients with ARDS compared with alveolar macrophages from healthy volunteers. This study reveals a critical role for myeloid MEK1 in promoting resolution of LPS-ALI and controlling the duration of macrophage proinflammatory responses.
- 5 December 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (23)
MEK1 regulates pulmonary macrophage inflammatory responses and resolution of acute lung injury
The MEK1/2–ERK1/2 pathway has been implicated in regulating the inflammatory response to lung injury and infection, and pharmacologic MEK1/2 inhibitor compounds are reported to reduce detrimental inflammation in multiple animal models of disease, in part through modulation of leukocyte responses. However, the specific contribution of myeloid MEK1 in regulating acute lung injury (ALI) and its resolution remain unknown. Here, the role of myeloid Mek1 was investigated in a murine model of LPS-induced ALI (LPS-ALI) by genetic deletion using the Cre-floxed system ( LysM Cre × Mek fl ), and human alveolar macrophages from healthy volunteers and patients with acute respiratory distress syndrome (ARDS) were obtained to assess activation of the MEK1/2–ERK1/2 pathway. Myeloid Mek1 deletion results in a failure to resolve LPS-ALI, and alveolar macrophages lacking MEK1 had increased activation of MEK2 and the downstream target ERK1/2 on day 4 of LPS-ALI. The clinical significance of these findings is supported by increased activation of the MEK1/2–ERK1/2 pathway in alveolar macrophages from patients with ARDS compared with alveolar macrophages from healthy volunteers. This study reveals a critical role for myeloid MEK1 in promoting resolution of LPS-ALI and controlling the duration of macrophage proinflammatory responses.
- 8 November 2019
- Published by Springer Nature in Lung
- Vol. 197 (6) , 819-823
Deletion of LysM in LysMCre Recombinase Homozygous Mice is Non-contributory in LPS-Induced Acute Lung Injury
Lysozyme is an important component of the innate immune system and has roles in peptidoglycan cleavage of gram-positive organisms. Myeloid cells highly express the isoform, lysozyme M, and its promoter has been used to direct Cre recombinase expression to target deletion of floxed genes in myeloid cells. However, generation of the LysMCre mouse effectively disrupts the LysM gene, and mice homozygous for the Cre allele lack the LysM gene product. To test the contribution of LysM in sterile acute lung injury, we generated LysMCre mice homozygous for the Cre allele (+/+) or wild-type allele (−/−). These mice were challenged with LPS delivered via oropharygneal aspiration. Mice were monitored and weighed daily, and BAL cell counts, differential, protein, and cytokine levels were assessed at days 2 and 4. LysMCre+/+ and LysMCre−/− had similar weight loss and recovery, and similar inflammatory responses to LPS at days 2 and 4. These findings indicate that loss of LysM and expression of Cre recombinase are non-contributory in sterile acute lung injury.
- 8 November 2019
- Published by Springer Nature in Lung
- Vol. 197 (6) , 819-823
Deletion of LysM in LysMCre Recombinase Homozygous Mice is Non-contributory in LPS-Induced Acute Lung Injury
Lysozyme is an important component of the innate immune system and has roles in peptidoglycan cleavage of gram-positive organisms. Myeloid cells highly express the isoform, lysozyme M, and its promoter has been used to direct Cre recombinase expression to target deletion of floxed genes in myeloid cells. However, generation of the LysMCre mouse effectively disrupts the LysM gene, and mice homozygous for the Cre allele lack the LysM gene product. To test the contribution of LysM in sterile acute lung injury, we generated LysMCre mice homozygous for the Cre allele (+/+) or wild-type allele (−/−). These mice were challenged with LPS delivered via oropharygneal aspiration. Mice were monitored and weighed daily, and BAL cell counts, differential, protein, and cytokine levels were assessed at days 2 and 4. LysMCre+/+ and LysMCre−/− had similar weight loss and recovery, and similar inflammatory responses to LPS at days 2 and 4. These findings indicate that loss of LysM and expression of Cre recombinase are non-contributory in sterile acute lung injury.